Related Experiment Video

Updated: Dec 21, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

737

Src family kinases and pulmonary fibrosis: A review

Hang Li1, Caiping Zhao1, Ye Tian1

  • 1TCM Innovation Center, Shenzhen Bao'an Traditional Chinese Medicine Hospital (Group), Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518133, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|May 11, 2020
PubMed

Insights

Src family kinases (SFKs) are implicated in pulmonary fibrosis (PF) pathogenesis. Targeting SFKs offers a promising therapeutic strategy for treating PF, including idiopathic pulmonary fibrosis (IPF).

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pathology

Background:

  • Src family kinases (SFKs) are non-receptor protein tyrosine kinases vital for cellular signaling.
  • While extensively studied in tumorigenesis, SFKs' role in pulmonary fibrosis (PF) is increasingly recognized.

Purpose of the Study:

  • To summarize the involvement of SFKs in the pathogenesis of pulmonary fibrosis.
  • To highlight SFKs as potential therapeutic targets for PF, particularly idiopathic pulmonary fibrosis (IPF).

Main Methods:

  • Review of existing literature on SFKs in pulmonary fibrosis.
  • Analysis of SFKs' roles in myofibroblast activation, epithelial-mesenchymal transition, and inflammation.
  • Examination of translational studies involving SFK inhibitors.

Main Results:

  • SFKs are crucial in key pathomechanisms of PF, including myofibroblast activation, epithelial-mesenchymal transition, and inflammation.
  • SFKs are implicated in the development of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.

Conclusions:

  • SFKs are pivotal in the pathogenesis of pulmonary fibrosis.
  • SFK inhibitors represent a promising therapeutic avenue for PF treatment, with ongoing basic and clinical investigations.
Keywords:
Epithelial-mesenchymal transitionInflammationMyofibroblast activationPulmonary fibrosisSrc family kinase

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

781
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.4K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
489
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
644
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K